ClinicalTrials.gg
Not yet recruitingNCT07218393EXPLORHAEUpdated Nov 20, 2026

A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt

An observational study in Hereditary Angioedema (HAE), sponsored by Takeda. Not yet recruiting at 7 sites in Egypt. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Takeda · Observational

How we know

Updated Nov 20, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
100
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 58 studies in Angioedemas, Hereditary by Takeda — 3 open to participants now, 4 under way, none of them phase 3. Angioedemas, Hereditary · Takeda.

Planned enrollment
9th of 21
100 · median 83
Started
2027
the only one that year
Observational
21 of 58
2 open now
Registered
54th of 58
by date

Among the 58 studies in Angioedemas, Hereditary by Takeda, this one is the 9th largest by planned enrollment of the 21 observational ones that give a count, is the only one that started in 2027, is one of 21 observational ones, and was the 54th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

3 of the 58 studies in Angioedemas, Hereditary by Takeda are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Angioedemas, Hereditary by Takeda, or all of them as a file.
02

Study summary

Hereditary angioedema (HAE) is a rare condition. It causes sudden swelling under the skin and inside the body, like in the belly, throat, or genitals. This swelling happens because of a temporary leak in blood vessels. HAE is classified based on the amount of a protein in the blood called C1 inhibitor (C1-INH): HAE with normal C1-INH levels and HAE with limited or insufficient C1-INH levels (C1-INH deficiency); HAE with C1-INH deficiency can be divided into Type1, with low levels of C1-INH, and Type 2, in which the protein is there, but does not work properly. This study will look at people with HAE Type1 or Type2.

The main aim of this study is to describe the diagnosis and management of people with HAE Type1 or HAE Type2 in Egypt. Other aims are to learn more about people with HAE Type1 or Type2, including, but not limited to, other conditions they may have, family history, impact of HAE on daily life, if treatment is stopped and the reasons.

During the study, information from already existing data in a participant's medical record will be reviewed and new data will be collected during routine visits of a participant to the study clinic.

03

Conditions studied

  • Hereditary Angioedema (HAE)
04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult and pediatric participants with HAE-C1INH type1 or type2, treated within a routine clinical setting in Egypt.

Eligibility criteria

Inclusion Criteria: Retrospective Phase:

  1. The participant has a confirmed HAE-C1INH type1 or type2 diagnosis in medical records (based on clinical history and/or laboratory diagnosis in medical records).
  2. The participant was diagnosed and/or treated from January 2015 to August 2025.

Inclusion Criteria: Prospective Phase:

  1. The participant has a physician-confirmed HAE-C1INH type1 or type2 diagnosis (based on clinical history and/or laboratory diagnosis).
  2. The participant signed an or assent.
  3. The participant should have had at least one visit to the treating physician/investigator during enrollment and the follow-up period.
  4. The participant was not enrolled in the study's retrospective phase.

Exclusion Criteria: (For both retrospective and prospective phases):

  1. Participant with AAE-C1INH (acquired angioedema), drug-induced angioedema (AE-DI) (example angiotensin-converting enzyme inhibitors-I [ACE-I] angioedema), allergic mediated angioedema, inflammatory angioedema, or idiopathic angioedema.
  2. HAE participants with normal C1-INH (HAE-nC1INH).
  3. Participant deemed unsuitable for participation for any reason, based on the investigator's clinical judgment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retrospective Phase

    All participants who were diagnosed with HAE-C1INH type1 or type2 from January 2015 to August 2025; retrospective clinical data will be extracted for 5 months exclusively from patients' medical charts, and no direct patient interaction will occur.

    Other: No intervention

  • Prospective Phase

    All participants with any newly diagnosed or admitted or follow-up HAE-C1INH type1 or type2; prospective clinical data will be actively collected over 12 months through routine visits and electronic data capture (EDC) entries.

    Other: No intervention

Interventions

  • OtherNo intervention

    This is a non-interventional study.

06

What researchers measure

Primary outcomes

  1. Age of Participants at Diagnosis (in years) of HAE-C1INH Type1 or Type2

    Time frame: At Day 1

  2. Percentage of Participants With HAE-C1INH Type1 or Type2

    Time frame: At Day 1

  3. Number and Type of First Symptom at Initial Manifestation

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  4. Number of Participants With First Symptom at Initial Manifestation

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  5. Duration of First Symptom at Initial Manifestation

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  6. Number and Type of Confirmed Diagnosis of HAE-C1INH Type1 or Type2

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  7. Number of Participants With Confirmed Diagnosis of HAE-C1INH Type1 or Type2

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  8. Duration of Confirmed Diagnosis of HAE-C1INH Type1 or Type2

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  9. Number of Participants with Recorded Diagnostic Test Results for C1-INH Antigenic Level, Serum Complement Component 4 (C4) Level, and C1-INH Functional Level

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  10. Number of Participants Receiving On-demand (OD), Short-term prophylaxis (STP), and Multiple Long-Term Prophylaxis (LTP) Therapies

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  11. Number of Participants who Received Prescriptions for Therapeutic Management With HAE-C1INH Type1 or Type2

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  12. Number of Treatment Options Used for the Therapeutic Management of Participants With HAE-C1INH Type1 or Type2

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  13. Number of Routes of Administration Used for the Therapeutic Management of Participants With HAE-C1INH Type1 or Type2

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  14. Number of Dose Regimens Used for the Therapeutic Management of Participants With HAE-C1INH Type1 or Type2

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  15. Number of Participants Switching Treatment for the Therapeutic Management of Participants With HAE-C1INH Type1 or Type2

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  16. Number of Participants With Frequency of Treatment Changes for the Therapeutic Management of Participants With HAE-C1INH Type1 or Type2

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  17. Number of Participants With Reason for Switching Treatment for the Therapeutic Management of Participants With HAE-C1INH Type1 or Type2

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

Secondary outcomes

  1. Number of Participants With Clinical Symptoms of HAE-C1INH Type1 or Type2 at Last Clinical Appointment

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  2. Number of Participants With Clinical Symptom Types of HAE-C1INH Type1 or Type2 at Last Clinical Appointment

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  3. Duration of Clinical Symptoms of HAE-C1INH Type1 or Type2 at Last Clinical Appointment

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  4. Number of Participants With Known Triggers at Diagnosis

    Triggers include stress, trauma, infection, contraception, menstruation, medication, food, burns, surgical procedures, and others.

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  5. Number of Participants With History of Upper Airway Edema

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  6. Number of Participants With History of Abdominal Surgery due to HAE Misdiagnosis

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  7. Number of Participants With HAE-related Death

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  8. Number of Participants With Response to Standard Allergy Medications

    Standard allergy medications (e.g. antihistamines, glucocorticoids, and epinephrine) that will be reported based on the symptom improvement, time to relief, reduction in symptom severity, and need for additional interventions.

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  9. Number of Participants With Presence of Comorbidities

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  10. Average Number of HAE Attacks per Month

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  11. Average Number of Attacks Requiring Acute Treatment per Month

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  12. Average Number of Attacks Requiring Emergency Care or Hospitalization per Month

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  13. Number of Participants With Severity of HAE Attack per Each Attack

    Number of participants with severity of HAE attack (mild, moderate, severe as reported or documented) per each attack.

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  14. Time of HAE Attack(s) at Each Onset During Follow-Up Visits or Date of Last Recorded HAE Attack

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  15. Duration of Symptoms for Each HAE Attack Onset During Subsequent Follow-Up Visits

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  16. Number of HAE Attacks per Month

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  17. Number of Participants Categorized by HAE Attack Characteristics

    HAE attack characteristics will include most common attack site(s) (e.g., abdominal, cutaneous, laryngeal), number of recurrent abdominal attacks, site of attack per each attack onset for each subsequent follow-up visit, and symptoms experienced per attack (e.g., pain, swelling, nausea).

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  18. Number of Participants With Prodromal Symptom

    Prodromal symptoms before attacks such as general discomfort, tiredness, irritability, skin symptoms, rash, and paresthesia per each attack onset for each subsequent follow-up visit will be reported.

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  19. Number of Participants With any Known Triggers Identified by the Participant as Related to the Onset of the Attack per Each Attack Onset for Each Subsequent Follow-up Visits

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  20. Number of Participants With On-demand Treatment Medication for Each HAE Attack

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  21. Number and Type of Hospitalizations due to HAE Attacks

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  22. Number of Participants With Life-threatening Attacks

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  23. Number of Participants (Family Members) Diagnosed With HAE-C1INH Type1 or Type2

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  24. Number of Participants With Degree of Relation (Parent, Sibling, Child) to Diagnosed Family Members

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  25. Number of Participants With Presence of Laryngeal or Life-threatening Attacks in Relatives

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  26. Number of Participants With Rate of Testing and of Diagnosis Among Tested Family Members

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  27. Number of Participants With History of HAE-related Deaths in the Family

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  28. Number of Participant's Relatives who Underwent Clinical and/or Lab Assessment for HAE diagnosis

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  29. Number of Participants With Clinical Assessment for HAE Diagnosis With Symptoms Description for the Patient, their Descendants, or Relatives

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  30. Number of Participants With Laboratory Testing for the Participant, Their Descendants, or Relatives

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  31. Number of Follow-up Visits Routinely Performed (Average per Year) During the Retrospective and Prospective Phase

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  32. Number of Participants Who Missed Days at Work or School and Social Life due to HAE Attack

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

  33. Number of Participants With Treatment Discontinuation

    Participants who discontinued the treatment due to reasons such as lack of efficacy, safety concerns, compliance issues, or others.

    Time frame: Up to 5 months retrospectively, up to 12 months prospectively

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2027, 10 months later.

Of 27 observational studies under Angioedemas, Hereditary, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 52. This study's planned 10 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Dec 2026 → Jan 2027, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2025
First posted
Oct 20, 2025
StartEst.
Jan 15, 2027was Dec 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 1, 2026→Jan 15, 2027
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Start date Dec 1, 2026→Jan 15, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07218393
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 20, 2025
Start date
Jan 15, 2027 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion